Sun Pharma buys controls of Taro
This article was originally published in The Tan Sheet
Executive Summary
The Indian firm acquires a majority stake in Taro Pharmaceutical Industries for $144 million - substantially less than its initial offer of $434 million for 100 percent of the firm three years ago. Sun Chairman and Managing Director Dilip Shanghvi takes over as chairman of Taro, which distributes primarily in Israel, Canada and the U.S. Taro's reported net sales reached $360.5 million in 2009. Sun has 48.7 percent economic interest in Taro and 65.8 percent voting rights on management decisions. Taro owner Barrie Levitt maintains a 12 percent stake, but has 41 percent voting rights. Sun Director Sudhir Valia is vice chair of Taro, and his son, Aalok Shanghvi, and Sun Director Hasmukh Shah were appointed directors. FDA has approved Taro private label equivalents of branded OTCs including McNeil Consumer Healthcare's Zyrtec allergy drug (1"The Tan Sheet" Aug. 10, 2009, In Brief)
You may also be interested in...
Taro gets generic Zyrtec go-ahead
FDA approves the Hawthorne, N.Y.-based company's abbreviated new drug application for 5-mg and 10-mg cetirizine hydrochloride tablets. Taro Pharmaceuticals said July 27 it previously received approval for an equivalent of Johnson & Johnson/McNeil's Children's Zyrtec Oral Solution (1"The Tan Sheet" April 28, 2008, In Brief). FDA has already approved private-label versions of the OTC allergy drug manufactured by Perrigo, Sandoz, Ranbaxy and Mylan
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.